Glaukos Corporation

NYSE: GKOS · Real-Time Price · USD
87.32
3.78 (4.52%)
At close: May 02, 2025, 3:59 PM
85.71
-1.84%
Pre-market: May 05, 2025, 05:46 AM EDT
4.52%
Bid 82
Market Cap 4.98B
Revenue (ttm) 404.52M
Net Income (ttm) -123.68M
EPS (ttm) -2.27
PE Ratio (ttm) -38.47
Forward PE -1385.08
Analyst Buy
Ask 94.25
Volume 1,962,851
Avg. Volume (20D) 1,066,382
Open 85.81
Previous Close 83.54
Day's Range 84.45 - 89.62
52-Week Range 77.10 - 163.71
Beta 0.88

About GKOS

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite, a three stent...

Sector Healthcare
IPO Date Jun 25, 2015
Employees 995
Stock Exchange NYSE
Ticker Symbol GKOS
Full Company Profile

Analyst Forecast

According to 13 analyst ratings, the average rating for GKOS stock is "Buy." The 12-month stock price forecast is $135, which is an increase of 54.60% from the latest price.

Stock Forecasts

Earnings Surprise

Glaukos has released their quartely earnings on Apr 30, 2025:
  • Revenue of $106.66M exceeds estimates by $3.88M, with 24.58% YoY growth.
  • EPS of -0.22 exceeds estimates by 0.13, with 68.57% YoY growth.
  • 4 days ago
    -11.36%
    Glaukos shares are trading lower after the company... Unlock content with Pro Subscription
    2 months ago
    -20.01%
    Glaukos shares are trading lower after the company reported Q4 Adj Eps miss.